Cquence AML/MDS genotyping panel
Are you a medical professional?

What are AML and MDS?

Acute myeloid leukemia (AML) refers to the cancer in the myeloid line of blood cells, which leads to the rapid growth of abnormal white blood cells inside the bone marrow. The myelodysplastic syndromes (MDS), or myelodysplasia, are medical conditions that affect the normal function of the bone marrow in creating blood cells. Thus, MDS is classified as one of the major precursors of AML.

How does this panel help treat AML?

Sometimes during diagnosis of AML or MDS, there are cases where doctors observe abnormal hematological behaviors in patients, like chronic anemia or bleeding. However, when they run the usual clinical tests, they all show “normal” results. All these unnatural behaviors can possibly be explained by gene mutations that are masked from the usual clinical tests. These genes are included in the panel to help provide molecular confirmation of the diagnosis.

This test enables doctors in determining the best medication for AML patients. Cquence AML/MDS genotyping panel is a precision medical test designed to detect and categorize (genotyping) nearly all of the mutation sites in 43 genes that are commonly involved in AML and MDS. Screening for these genes help doctors identify the root cause when making decisions for the patient. Also, the information of these genes also plays an important role in determining and monitoring the treatment response.

What are the genes in the panel and how are they related to AML/MDS?

The major difference which separates a cancer cell from a normal cell is its uncontrolled cell growth with an exceptionally higher survival rate. These “enhanced” abilities are contributed by changes in the genetic information, or genes, of these cancer cells. Some of these changes, like JAK2, lead to uncontrolled cell growth of abnormal blood cells.

Who should consider this test?

Patients who are suffering or suspected of AML or MDS; and patients who have received or receiving treatment are suggested to perform this test.

Test Specifications

Test Code
Methodology
Specimen Requirements
Turnaround Time
OKA
Next generation sequencing (NGS)
6 mL blood in EDTA tube
17 days

What should I do if my test results are positive?

Please consult your physicians for professional advices.

How to get started

Our tests must be ordered by a doctor. Ask your doctor if a Mygenia test is right for you. We can help you find a doctor if you don’t have one.

I have a doctor